Statistics from Altmetric.com
With great interest we read the paper by Dotti et al,1 who identified a set of differentially expressed genes in epithelial organoid cultures (EpOCs) derived from patients with UC compared with EpOCs from healthy controls.
Similarly, we created an EpOC library from patients with UC (n=17), Crohn's disease (CD, n=12) and healthy controls (n=10). First, we assessed the potential of isolated intestinal crypts to grow into organoids (colony forming units). We observed that a similar percentage of organoids was formed from intestinal crypts isolated from controls and patients with UC or CD. Moreover, intestinal crypts isolated from macroscopically inflamed and non-inflamed tissue had similar potential to form organoids (figure 1A). Although we used a slightly divergent differentiation medium,2 the expansion and differentiation capacity of our organoids was similar as demonstrated by Dotti et al.
Contributors MN: conception and design of the work, acquisition, analysis and interpretation of data, manuscript writing. BV: data analysis, manuscript writing. MdB: conception and design of the work and manuscript writing. GVA: acquisition, manuscript approval. SV: acquisition, manuscript writing, manuscript approval. CV: analysis and interpretation of data, manuscript approval. MF: conception and design of the work, acquisition, analysis and interpretation of data, manuscript writing and final approval.
Funding This study was partially funded by a CREA research grant of the KU Leuven (CREA/12/031), and a research grant by the European Crohn's and Colitis Organization (ZKC4621/10143459). MN and BV are doctoral fellows, and GVA, SV and MF are senior clinical investigators of the Research Foundation—Flanders (FWO).
Competing interests SV: Grant support: AbbVie, MSD and Takeda; Speaker fees: AbbVie, MSD, Takeda, Ferring, Dr Falk Pharma, Hospira, Pfizer and Tillots; Consultancy: AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer, Galapagos, Mundipharma, Hospira, Celgene, Second Genome and Janssen. GVA: Financial support for research: Abbvie, MSD; Lecture fees: Abbvie, Ferring, MSD, Janssen, Takeda; Consultancy: Abbvie, MSD, Takeda. MF: Research grant: Takeda; Speakers fee: Abbvie, Boehringer-Ingelheim, Chiesi, Falk, Ferring, Janssen, Mitsubishi Tanabe, MSD, Takeda, Tillotts, Zeria; Consultancy: Abbvie, Boehringer-Ingelheim, Ferring, Janssen, MSD.
Ethics approval The study was approved of by the ethics committee of the University Hospitals Leuven, Belgium (ML7771).
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.